Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Goldblatt

Showing results (231-240 of 242) with videos related to

Pageof 25
Sort By:
Vaccine|January 7, 2026
Determining the dose-response relationship for pneumococcal conjugate vaccines: a nested analysis of the fractional dose PCV trialIrene Martinez-de-Albeniz, Christian Bottomley, Ruth Lucinde, et al.
Clinical and Vaccine Immunology : CVI|November 19, 2010
Multilaboratory comparison of Streptococcus pneumoniae opsonophagocytic killing assays and their level of agreement for the determination of functional antibody activity in human reference seraCharles E Rose, Sandra Romero-Steiner, Robert L Burton, et al.
The Pediatric Infectious Disease Journal|July 22, 2021
Persistence of Immunity Following 2-Dose Priming with a 10-Valent Pneumococcal Conjugate Vaccine at 6 and 10 Weeks or 6 and 14 Weeks of Age in Nepalese ToddlersMeeru Gurung, Sanjeev M Bijukchhe, Parisa Hariri, et al.
Nature Medicine|February 22, 2023
When to update COVID-19 vaccine compositionRebecca Grant, Jilian A Sacks, Priya Abraham, et al.
Journal of Clinical Immunology|April 16, 2025
Safety and Diagnostic Utility of Brain Biopsy and Metagenomics in Decision-Making for Patients with Inborn Errors of Immunity (IEI) and Unexplained Neurological ManifestationsJesmeen Maimaris, Julia Payne, Adriel Roa-Bautista, et al.
American Journal of Respiratory and Critical Care Medicine|September 17, 2020
Experimental Human Pneumococcal Colonization in Older Adults Is Feasible and Safe, Not ImmunogenicHugh Adler, Esther L German, Elena Mitsi, et al.
Iscience|January 18, 2024
Distinct T cell polyfunctional profile in SARS-CoV-2 seronegative children associated with endemic human coronavirus cross-reactivityNtombi Benede, Marius B Tincho, Avril Walters, et al.
Nature Cancer|March 25, 2022
Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO studySean H Lim, Beth Stuart, Debora Joseph-Pietras, et al.
Nature|November 10, 2021
Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2Leo Swadling, Mariana O Diniz, Nathalie M Schmidt, et al.
Vaccine|January 1, 2013
Priorities for research on meningococcal disease and the impact of serogroup A vaccination in the African meningitis belt, Danny Altmann, Abraham Aseffa, et al.
Pageof 25

Showing results (231-240 of 242) with videos related to

Sort By:
Pageof 25
Vaccine|January 7, 2026
Determining the dose-response relationship for pneumococcal conjugate vaccines: a nested analysis of the fractional dose PCV trialIrene Martinez-de-Albeniz, Christian Bottomley, Ruth Lucinde, et al.
Clinical and Vaccine Immunology : CVI|November 19, 2010
Multilaboratory comparison of Streptococcus pneumoniae opsonophagocytic killing assays and their level of agreement for the determination of functional antibody activity in human reference seraCharles E Rose, Sandra Romero-Steiner, Robert L Burton, et al.
The Pediatric Infectious Disease Journal|July 22, 2021
Persistence of Immunity Following 2-Dose Priming with a 10-Valent Pneumococcal Conjugate Vaccine at 6 and 10 Weeks or 6 and 14 Weeks of Age in Nepalese ToddlersMeeru Gurung, Sanjeev M Bijukchhe, Parisa Hariri, et al.
Nature Medicine|February 22, 2023
When to update COVID-19 vaccine compositionRebecca Grant, Jilian A Sacks, Priya Abraham, et al.
Journal of Clinical Immunology|April 16, 2025
Safety and Diagnostic Utility of Brain Biopsy and Metagenomics in Decision-Making for Patients with Inborn Errors of Immunity (IEI) and Unexplained Neurological ManifestationsJesmeen Maimaris, Julia Payne, Adriel Roa-Bautista, et al.
American Journal of Respiratory and Critical Care Medicine|September 17, 2020
Experimental Human Pneumococcal Colonization in Older Adults Is Feasible and Safe, Not ImmunogenicHugh Adler, Esther L German, Elena Mitsi, et al.
Iscience|January 18, 2024
Distinct T cell polyfunctional profile in SARS-CoV-2 seronegative children associated with endemic human coronavirus cross-reactivityNtombi Benede, Marius B Tincho, Avril Walters, et al.
Nature Cancer|March 25, 2022
Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO studySean H Lim, Beth Stuart, Debora Joseph-Pietras, et al.
Nature|November 10, 2021
Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2Leo Swadling, Mariana O Diniz, Nathalie M Schmidt, et al.
Vaccine|January 1, 2013
Priorities for research on meningococcal disease and the impact of serogroup A vaccination in the African meningitis belt, Danny Altmann, Abraham Aseffa, et al.
Pageof 25